445 related articles for article (PubMed ID: 32975842)
1. COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2.
Mondi A; Cimini E; Colavita F; Cicalini S; Pinnetti C; Matusali G; Casetti R; Maeurer M; Vergori A; Mazzotta V; Gagliardini R; De Zottis F; Schininà V; Girardi E; Puro V; Ippolito G; Vaia F; Capobianchi MR; Castilletti C; Agrati C; Antinori A
J Med Virol; 2021 Mar; 93(3):1796-1804. PubMed ID: 32975842
[TBL] [Abstract][Full Text] [Related]
2. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count.
Antinori A; Cicalini S; Meschi S; Bordoni V; Lorenzini P; Vergori A; Lanini S; De Pascale L; Matusali G; Mariotti D; Cozzi Lepri A; Gallì P; Pinnetti C; Gagliardini R; Mazzotta V; Mastrorosa I; Grisetti S; Colavita F; Cimini E; Grilli E; Bellagamba R; Lapa D; Sacchi A; Marani A; Cerini C; Candela C; Fusto M; Puro V; Castilletti C; Agrati C; Girardi E; Vaia F;
Clin Infect Dis; 2022 Aug; 75(1):e552-e563. PubMed ID: 35366316
[TBL] [Abstract][Full Text] [Related]
3. Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy.
Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Huang SH; Huang YC; Su YC; Liu WC; Hung CC
Int J Infect Dis; 2021 Apr; 105():147-151. PubMed ID: 33592339
[TBL] [Abstract][Full Text] [Related]
4. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
[TBL] [Abstract][Full Text] [Related]
5. CROI 2021: Advances in Antiretroviral Therapy for HIV and Antiviral Therapy for COVID-19.
Gunaratne SH; Tieu HV; Wilkin TJ; Taylor BS
Top Antivir Med; 2021; 29(3):361-378. PubMed ID: 34370418
[TBL] [Abstract][Full Text] [Related]
6. Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection: A case report.
d'Ettorre G; Recchia G; Ridolfi M; Siccardi G; Pinacchio C; Innocenti GP; Santinelli L; Frasca F; Bitossi C; Ceccarelli G; Borrazzo C; Antonelli G; Scagnolari C; Mastroianni CM
Medicine (Baltimore); 2020 Sep; 99(36):e21803. PubMed ID: 32899009
[TBL] [Abstract][Full Text] [Related]
7. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
8. Cases of coronavirus disease-2019 in HIV-infected transgender women.
Adachi E; Saito M; Ikeuchi K; Hoshina T; Yotsuyanagi H
AIDS; 2020 Jul; 34(9):1435-1436. PubMed ID: 32590441
[No Abstract] [Full Text] [Related]
9. COVID-19 and HIV infection co-pandemics and their impact: a review of the literature.
Gatechompol S; Avihingsanon A; Putcharoen O; Ruxrungtham K; Kuritzkes DR
AIDS Res Ther; 2021 May; 18(1):28. PubMed ID: 33952300
[TBL] [Abstract][Full Text] [Related]
10. Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy.
Jedicke N; Stankov MV; Cossmann A; Dopfer-Jablonka A; Knuth C; Ahrenstorf G; Ramos GM; Behrens GMN
HIV Med; 2022 May; 23(5):558-563. PubMed ID: 34725907
[TBL] [Abstract][Full Text] [Related]
11. Increase in Body Mass Index in Children With HIV, Switched to Tenofovir Alafenamide Fumarate or Dolutegravir Containing Antiretroviral Regimens.
Yeoh DK; Campbell AJ; Bowen AC
Pediatr Infect Dis J; 2021 May; 40(5):e215-e216. PubMed ID: 33847305
[No Abstract] [Full Text] [Related]
12. Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) co-infection with HIV: clinical case series analysis in North Central Nigeria.
Akyala AI; Iwu CJ
Pan Afr Med J; 2020; 37():47. PubMed ID: 33209174
[TBL] [Abstract][Full Text] [Related]
13. Factors Associated with Severe COVID-19 and Post-Acute COVID-19 Syndrome in a Cohort of People Living with HIV on Antiretroviral Treatment and with Undetectable HIV RNA.
Mazzitelli M; Trunfio M; Sasset L; Leoni D; Castelli E; Lo Menzo S; Gardin S; Putaggio C; Brundu M; Garzotto P; Cattelan AM
Viruses; 2022 Feb; 14(3):. PubMed ID: 35336900
[TBL] [Abstract][Full Text] [Related]
14. Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV.
Lee YL; Lin KY; Cheng SH; Lu PL; Wang NC; Ho MW; Yang CJ; Liou BH; Tang HJ; Huang SS; Huang SH; Chen TC; Lin CY; Lin SP; Lee YT; Hung CC;
Int J Antimicrob Agents; 2021 Sep; 58(3):106403. PubMed ID: 34289404
[TBL] [Abstract][Full Text] [Related]
15. Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV.
Sangaré MN; Baril JG; de Pokomandy A; Laprise C; Deshaies C; Klein M; Thomas R; Tremblay C; Roger M; Pexos C; Greenwald Z; Machouf N; Durand M; Hardy I; Dakouo M; Laporte L; Trottier H
Medicine (Baltimore); 2020 Nov; 99(47):e23335. PubMed ID: 33217873
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 diversity and the implementation of integrase strand-transfer inhibitors as part of combination antiretroviral therapy.
Mikasi SG; Ikomey GM; Obasa AE; Cloete R; Jacobs GB
S Afr Med J; 2020 Aug; 110(9):13071. PubMed ID: 32880259
[No Abstract] [Full Text] [Related]
17. Short-cycle therapy (5 days on/2 days off) with a lamivudine + dolutegravir regimen in a cohort of virologically suppressed patients with HIV infection.
Lanzafame M; Lattuada E; Gottardo R; Piacentini D; Be G; Razzaboni E; Cattaneo P; Luise D; Vento S
Int J Antimicrob Agents; 2021 Mar; 57(3):106290. PubMed ID: 33513407
[No Abstract] [Full Text] [Related]
18. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0.
Ryom L; Cotter A; De Miguel R; Béguelin C; Podlekareva D; Arribas JR; Marzolini C; Mallon P; Rauch A; Kirk O; Molina JM; Guaraldi G; Winston A; Bhagani S; Cinque P; Kowalska JD; Collins S; Battegay M;
HIV Med; 2020 Nov; 21(10):617-624. PubMed ID: 32885559
[TBL] [Abstract][Full Text] [Related]
19. Body Fat Distribution and Metabolic Changes in a Cohort of Adolescents Living With HIV Switched to an Antiretroviral Regimen Containing Dolutegravir.
Giacomet V; Lazzarin S; Manzo A; Paradiso L; Maruca K; Barera G; Zuccotti GV; Mora S
Pediatr Infect Dis J; 2021 May; 40(5):457-459. PubMed ID: 33847293
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
Viani RM; Ruel T; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Palumbo P; Buchanan AM; Vavro C; Singh R; Graham B; Anthony P; George K; Wiznia A;
J Pediatric Infect Dis Soc; 2020 Apr; 9(2):159-165. PubMed ID: 30951600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
